These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 34934147)

  • 1. CD99 antibody disrupts T-cell acute lymphoblastic leukemia adhesion to meningeal cells and attenuates chemoresistance.
    Ebadi M; Jonart LM; Ostergaard J; Gordon PM
    Sci Rep; 2021 Dec; 11(1):24374. PubMed ID: 34934147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CXCR4 antagonists disrupt leukaemia-meningeal cell adhesion and attenuate chemoresistance.
    Jonart LM; Ostergaard J; Brooks A; Fitzpatrick G; Chen L; Gordon PM
    Br J Haematol; 2023 May; 201(3):459-469. PubMed ID: 36535585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disrupting the leukemia niche in the central nervous system attenuates leukemia chemoresistance.
    Jonart LM; Ebadi M; Basile P; Johnson K; Makori J; Gordon PM
    Haematologica; 2020 Aug; 105(8):2130-2140. PubMed ID: 31624109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-valency Anti-CD99 Antibodies Toward the Treatment of T Cell Acute Lymphoblastic Leukemia.
    Romero LA; Hattori T; Ali MAE; Ketavarapu G; Koide A; Park CY; Koide S
    J Mol Biol; 2022 Mar; 434(5):167402. PubMed ID: 34958778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CAR T cells targeting CD99 as an approach to eradicate T-cell acute lymphoblastic leukemia without normal blood cells toxicity.
    Shi J; Zhang Z; Cen H; Wu H; Zhang S; Liu J; Leng Y; Ren A; Liu X; Zhang Z; Tong X; Liang J; Li Z; Zhou F; Huang L; Qin Y; Yang K; Zhang T; Zhu H
    J Hematol Oncol; 2021 Oct; 14(1):162. PubMed ID: 34627328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigating CD99 Expression in Leukemia Propagating Cells in Childhood T Cell Acute Lymphoblastic Leukemia.
    Cox CV; Diamanti P; Moppett JP; Blair A
    PLoS One; 2016; 11(10):e0165210. PubMed ID: 27764235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cell adhesion-mediated mitochondria transfer contributes to mesenchymal stem cell-induced chemoresistance on T cell acute lymphoblastic leukemia cells.
    Wang J; Liu X; Qiu Y; Shi Y; Cai J; Wang B; Wei X; Ke Q; Sui X; Wang Y; Huang Y; Li H; Wang T; Lin R; Liu Q; Xiang AP
    J Hematol Oncol; 2018 Jan; 11(1):11. PubMed ID: 29357914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Do preclinical studies suggest that CD99 is a potential therapeutic target in acute myeloid leukemia and the myelodysplastic syndromes?
    Tavakkoli M; Chung SS; Park CY
    Expert Opin Ther Targets; 2018 May; 22(5):381-383. PubMed ID: 29637789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting cytokine- and therapy-induced PIM1 activation in preclinical models of T-cell acute lymphoblastic leukemia and lymphoma.
    De Smedt R; Morscio J; Reunes L; Roels J; Bardelli V; Lintermans B; Van Loocke W; Almeida A; Cheung LC; Kotecha RS; Mansour MR; Uyttebroeck A; Vandenberghe P; La Starza R; Mecucci C; Lammens T; Van Roy N; De Moerloose B; Barata JT; Taghon T; Goossens S; Van Vlierberghe P
    Blood; 2020 May; 135(19):1685-1695. PubMed ID: 32315407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Senescent stromal cell-induced divergence and therapeutic resistance in T cell acute lymphoblastic leukemia/lymphoma.
    Habiel DM; Krepostman N; Lilly M; Cavassani K; Coelho AL; Shibata T; Elenitoba-Johnson K; Hogaboam CM
    Oncotarget; 2016 Dec; 7(50):83514-83529. PubMed ID: 27835864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic high-dose ara-C for the treatment of meningeal leukemia in adult acute lymphoblastic leukemia and non-Hodgkin's lymphoma.
    Morra E; Lazzarino M; Inverardi D; Brusamolino E; Orlandi E; Canevari A; Pagnucco G; Bernasconi C
    J Clin Oncol; 1986 Aug; 4(8):1207-11. PubMed ID: 3461134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic antibody targeting of Notch1 in T-acute lymphoblastic leukemia xenografts.
    Agnusdei V; Minuzzo S; Frasson C; Grassi A; Axelrod F; Satyal S; Gurney A; Hoey T; Seganfreddo E; Basso G; Valtorta S; Moresco RM; Amadori A; Indraccolo S
    Leukemia; 2014 Feb; 28(2):278-88. PubMed ID: 23774673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The CNS microenvironment promotes leukemia cell survival by disrupting tumor suppression and cell cycle regulation in pediatric T-cell acute lymphoblastic leukemia.
    Enlund S; Sinha I; Neofytou C; Amor AR; Papadakis K; Nilsson A; Jiang Q; Hermanson O; Holm F
    Exp Cell Res; 2024 Apr; 437(2):114015. PubMed ID: 38561062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beta1 integrin blockade overcomes doxorubicin resistance in human T-cell acute lymphoblastic leukemia.
    Berrazouane S; Boisvert M; Salti S; Mourad W; Al-Daccak R; Barabé F; Aoudjit F
    Cell Death Dis; 2019 May; 10(5):357. PubMed ID: 31043590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel Monoclonal Antibody against Notch1 Targets Leukemia-associated Mutant Notch1 and Depletes Therapy Resistant Cancer Stem Cells in Solid Tumors.
    Sharma A; Gadkari RA; Ramakanth SV; Padmanabhan K; Madhumathi DS; Devi L; Appaji L; Aster JC; Rangarajan A; Dighe RR
    Sci Rep; 2015 Jun; 5():11012. PubMed ID: 26046801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Flow cytometric evaluation of CD38 expression levels in the newly diagnosed T-cell acute lymphoblastic leukemia and the effect of chemotherapy on its expression in measurable residual disease, refractory disease and relapsed disease: an implication for anti-CD38 immunotherapy.
    Tembhare PR; Sriram H; Khanka T; Chatterjee G; Panda D; Ghogale S; Badrinath Y; Deshpande N; Patkar NV; Narula G; Bagal B; Jain H; Sengar M; Khattry N; Banavali S; Gujral S; Subramanian PG
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triggering of CD99 on monocytes by a specific monoclonal antibody regulates T cell activation.
    Laopajon W; Pata S; Takheaw N; Surinkaew S; Khummuang S; Kasinrerk W
    Cell Immunol; 2019 Jan; 335():51-58. PubMed ID: 30396687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TFDP3 confers chemoresistance in minimal residual disease within childhood T-cell acute lymphoblastic leukemia.
    Chu M; Yin K; Dong Y; Wang P; Xue Y; Zhou P; Wang Y; Wang Y
    Oncotarget; 2017 Jan; 8(1):1405-1415. PubMed ID: 27902457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-CD99 scFv-ELP nanoworms for the treatment of acute myeloid leukemia.
    Vaikari VP; Park M; Keossayan L; MacKay JA; Alachkar H
    Nanomedicine; 2020 Oct; 29():102236. PubMed ID: 32535112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell Adhesion Molecule CD99 in Cancer Immunotherapy.
    Yu F; Liu G; Zhang H; Wang X; Wu Z; Xu Q; Wu Y; Chen D
    Curr Mol Med; 2023; 23(10):1028-1036. PubMed ID: 36214301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.